drugset
drugset / Trial / NCT04544748

A Phase 1 Study of GNR-051 in Subjects With Advanced Malignancies

NCT04544748 ↗

Phase 1 Unknown 48 enrolled AO GENERIUM
Non-randomizedSequentialOpen-labelTreatment

Summary

It is a Phase 1 Multicenter Open-Label Multi-Cohort Dose-Escalation Study to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity of GNR-051 in Subjects with Advanced Solid Malignancies.

Timeline

Start
2020-07-22
Primary completion
2022-11-07
Completion
2025-01

Drugs

EvaluationDrugModalityDoseRoute
Subject GNR-051 Monoclonal antibody 0.1 mg/kg —
Subject GNR-051 Monoclonal antibody 0.3 mg/kg —
Subject GNR-051 Monoclonal antibody 1 mg/kg —
Subject GNR-051 Monoclonal antibody 3 mg/kg —
Subject GNR-051 Monoclonal antibody 10 mg/kg —

Indications

melanoma non-small cell lung carcinoma renal cell carcinoma